Free Trial

Psyence Biomedical (PBM) Competitors

Psyence Biomedical logo
$5.12 +0.16 (+3.23%)
Closing price 07/11/2025 03:58 PM Eastern
Extended Trading
$5.16 +0.04 (+0.68%)
As of 07/11/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PBM vs. ACXP, BCDA, CSCI, CLDI, SNPX, PHXM, ADXN, GLYC, CYCN, and XFOR

Should you be buying Psyence Biomedical stock or one of its competitors? The main competitors of Psyence Biomedical include Acurx Pharmaceuticals (ACXP), BioCardia (BCDA), COSCIENS Biopharma (CSCI), Calidi Biotherapeutics (CLDI), Synaptogenix (SNPX), PHAXIAM Therapeutics (PHXM), Addex Therapeutics (ADXN), GlycoMimetics (GLYC), Cyclerion Therapeutics (CYCN), and X4 Pharmaceuticals (XFOR). These companies are all part of the "pharmaceutical products" industry.

Psyence Biomedical vs. Its Competitors

Acurx Pharmaceuticals (NASDAQ:ACXP) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Psyence Biomedical's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Acurx PharmaceuticalsN/A -526.78% -223.78%
Psyence Biomedical N/A N/A N/A

Acurx Pharmaceuticals presently has a consensus target price of $8.00, suggesting a potential upside of 1,591.33%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Acurx Pharmaceuticals is more favorable than Psyence Biomedical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acurx Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Psyence Biomedical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Acurx Pharmaceuticals has a beta of -1.23, suggesting that its stock price is 223% less volatile than the S&P 500. Comparatively, Psyence Biomedical has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500.

In the previous week, Acurx Pharmaceuticals had 1 more articles in the media than Psyence Biomedical. MarketBeat recorded 2 mentions for Acurx Pharmaceuticals and 1 mentions for Psyence Biomedical. Psyence Biomedical's average media sentiment score of 1.89 beat Acurx Pharmaceuticals' score of 0.94 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company Overall Sentiment
Acurx Pharmaceuticals Positive
Psyence Biomedical Very Positive

11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 26.0% of Acurx Pharmaceuticals shares are held by insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acurx PharmaceuticalsN/AN/A-$14.10M-$0.70-0.68
Psyence BiomedicalN/AN/A$1.01MN/AN/A

Summary

Psyence Biomedical beats Acurx Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Get Psyence Biomedical News Delivered to You Automatically

Sign up to receive the latest news and ratings for PBM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PBM vs. The Competition

MetricPsyence BiomedicalMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.92M$2.93B$5.54B$9.08B
Dividend YieldN/A2.45%5.07%4.02%
P/E RatioN/A20.9928.2720.33
Price / SalesN/A284.46429.65104.57
Price / Cash2.8741.0526.2427.98
Price / Book0.437.638.125.50
Net Income$1.01M-$55.05M$3.19B$250.38M
7 Day Performance4.49%7.11%3.68%2.19%
1 Month Performance12.78%8.14%7.70%10.92%
1 Year Performance-97.24%1.62%29.39%16.41%

Psyence Biomedical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PBM
Psyence Biomedical
0.986 of 5 stars
$5.12
+3.2%
N/A-97.2%$2.92MN/A0.00N/APositive News
ACXP
Acurx Pharmaceuticals
2.5731 of 5 stars
$0.49
+3.6%
$8.00
+1,537.7%
-79.5%$11.07MN/A-0.703
BCDA
BioCardia
3.5006 of 5 stars
$2.29
+9.0%
$25.00
+991.7%
-26.5%$10.87M$60K-0.9840Positive News
CSCI
COSCIENS Biopharma
N/A$3.65
+6.1%
N/AN/A$10.82M$9.59M-0.6320
CLDI
Calidi Biotherapeutics
0.5553 of 5 stars
$0.34
+39.5%
N/A-52.0%$10.65MN/A0.0038Gap Down
High Trading Volume
SNPX
Synaptogenix
0.3164 of 5 stars
$7.63
-10.2%
$14.00
+83.5%
+99.3%$10.61MN/A-0.764Positive News
Gap Down
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat
N/AN/A$10.58MN/A0.0049
ADXN
Addex Therapeutics
2.5301 of 5 stars
$9.52
+1.5%
$30.00
+215.1%
+7.1%$10.05M$460K-28.0030Positive News
Gap Down
GLYC
GlycoMimetics
0.9866 of 5 stars
$0.16
-6.6%
N/A-99.5%$10.00M$10K-0.3450High Trading Volume
CYCN
Cyclerion Therapeutics
2.0217 of 5 stars
$3.14
+1.6%
N/A+9.6%$9.92M$2M-2.7130
XFOR
X4 Pharmaceuticals
4.9382 of 5 stars
$1.67
-1.2%
$72.33
+4,244.3%
-93.2%$9.75M$2.56M0.7880Positive News
High Trading Volume

Related Companies and Tools


This page (NASDAQ:PBM) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners